These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1425891)

  • 1. Pharmacokinetic profile of a novel slow release preparation of molsidomine.
    Rietbrock S; Keller-Stanislawski B; Thürmann P; Brockmeier D
    Eur J Clin Pharmacol; 1992; 43(3):273-6. PubMed ID: 1425891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vivo and in-vitro correlation for delayed-release behaviour of a molsidomine/O-carboxymethyl-O-ethyl-beta-cyclodextrin complex in gastric acidity-controlled dogs.
    Horikawa T; Hirayama F; Uekama K
    J Pharm Pharmacol; 1995 Feb; 47(2):124-7. PubMed ID: 7602466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of the controlled-release nisoldipine coat-core tablet formulation.
    Heinig R; Ahr G; Hayauchi Y; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):341-51. PubMed ID: 9266290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics of molsidomine.
    Rosenkranz B; Winkelmann BR; Parnham MJ
    Clin Pharmacokinet; 1996 May; 30(5):372-84. PubMed ID: 8743336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peracylated beta-cyclodextrins as novel sustained-release carriers for a water-soluble drug, molsidomine.
    Uekama K; Horikawa T; Yamanaka M; Hirayama F
    J Pharm Pharmacol; 1994 Sep; 46(9):714-7. PubMed ID: 7837039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitigation of Adverse Clinical Events of a Narrow Target Therapeutic Index Compound through Modified Release Formulation Design: An in Vitro, in Vivo, in Silico, and Clinical Pharmacokinetic Analysis.
    Good DJ; Hartley R; Mathias N; Crison J; Tirucherai G; Timmins P; Hussain M; Haddadin R; Koo O; Nikfar F; Fung NK
    Mol Pharm; 2015 Dec; 12(12):4434-44. PubMed ID: 26536519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast.
    Schug BS; Brendel E; Chantraine E; Wolf D; Martin W; Schall R; Blume HH
    Br J Clin Pharmacol; 2002 Jun; 53(6):582-8. PubMed ID: 12047482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation and evaluation of sustained release paracetamol tablets.
    Ahmed M; Enever RP
    J Clin Hosp Pharm; 1981 Mar; 6(1):27-38. PubMed ID: 7345094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly.
    Spreux-Varoquaux O; Ulmer B; Cordonnier P; Forestier A; Pays M; Ducreuzet C; Advenier C
    Fundam Clin Pharmacol; 1991; 5(6):549-56. PubMed ID: 1955198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers.
    Deroubaix X; Lins RL; Lens S; Demblon C; Jeanbaptiste B; Poelaert D; Stockis A
    Int J Clin Pharmacol Ther; 1996 Feb; 34(2):61-70. PubMed ID: 8929748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral sustained release clonidine in humans.
    MacGregor TR; Relihan GL; Keirns JJ
    Arzneimittelforschung; 1985; 35(1A):440-6. PubMed ID: 4039184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation.
    Chung M; Vashi V; Puente J; Sweeney M; Meredith P
    Br J Clin Pharmacol; 1999 Nov; 48(5):678-87. PubMed ID: 10594469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.
    Messin R; Fenyvesi T; Carreer-Bruhwyler F; Crommen J; Chiap P; Hubert P; Dubois C; Famaey JP; Géczy J
    Eur J Clin Pharmacol; 2003 Jul; 59(3):227-32. PubMed ID: 12734607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-dynamic study on different oral biperiden formulations in volunteers.
    Hollmann M; Müller-Peltzer H; Greger G; Brode E; Perucca E; Grimaldi R; Crema A
    Pharmacopsychiatry; 1987 Mar; 20(2):72-7. PubMed ID: 3588663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of an oral prolonged-release antibiotic formulation.
    Schneider H; Nightingale CH; Quintiliani R; Flanagan DR
    J Pharm Sci; 1978 Nov; 67(11):1620-2. PubMed ID: 712604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.